Dyne Therapeutics
Develops targeted genetic medicines for neuromuscular diseases through its FORCE delivery platform.
Something off on this page? Send us feedback.
Profile
Develops FORCE-platform therapeutics that carry oligonucleotide or enzyme payloads into muscle and the central nervous system. The pipeline is led by late-stage programs for Duchenne muscular dystrophy and myotonic dystrophy type 1; no product is approved, and manufacturing is outsourced.
Develops targeted therapies for genetically driven neuromuscular diseases using the FORCE platform, which couples a transferrin-receptor-targeting antibody fragment to oligonucleotide or enzyme payloads. The design aims to deliver medicines into skeletal, cardiac and smooth muscle and the central nervous system. Programs span Duchenne muscular dystrophy, myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy and Pompe disease.
Lead programs are z-rostudirsen for exon-skipping-amenable Duchenne and z-basivarsen for myotonic dystrophy; both are in global late-stage development, and the former is under priority FDA review. The FSHD program has clearance to enter human testing, while the Pompe disease program remains preclinical. Commercial revenue depends on regulatory approval, and manufacturing is outsourced to contract organizations.
Company facts
Key statistics
Year to date +35.6% · Average volume (30d) 2.3M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 17, 2026 | H.C. Wainwright | Reiterate | Buy | $60 | $50 |
| Jul 31, 2026 | Morgan Stanley | Reiterate | Overweight | $47 | $45 |
| Jul 23, 2026 | Cantor Fitzgerald | Initiate | Overweight | ||
| Jun 26, 2026 | Cowen & Co. | Initiate | Buy | ||
| May 15, 2026 | Evercore ISI | Target | $36 | $33 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | −$0.75 | −$1.08 | −44.2% | — | — | — | −2.14% |
| May 11, 2026Q1 FY26 | −$0.77 | −$0.73 | +5.5% | — | — | — | −0.49% |
| Mar 2, 2026Q4 FY25 | −$0.74 | −$0.76 | −2.7% | — | — | — | −9.60% |
| Nov 5, 2025Q3 FY25 | −$0.81 | −$0.76 | +6.2% | — | — | — | −12.92% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | −$521.0K | $0 | $0 | |
| Operating income | −$122.4M | −$115.8M | −$113.9M | −$116.1M | −$125.3M | −$181.7M | |
| Net income | −$115.4M | −$110.9M | −$108.0M | −$112.0M | −$120.9M | −$178.6M | |
| Diluted EPS | −$1.05 | −$0.97 | −$0.76 | −$0.76 | −$0.73 | −$1.08 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $898.5M · Total debt $19.9M · Total assets $994.0M · Shareholders' equity $702.2M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 186.75M · Float 152.33M · 81.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 30.91M | 16.55% | 13F | Aug 14, 2026 |
| Janus Henderson Group PLC | 13.65M | 8.30% | 13G | May 15, 2026 |
| BlackRock, Inc. | 12.40M | 6.64% | 13F | Aug 7, 2026 |
| Jupiter Topco LLC | 12.00M | 6.42% | 13F | Aug 14, 2026 |
| FMR LLC | 11.21M | 6.00% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 13, 2026 | Jason P. Rhodes | director | −426,412 | $26.20 |
| Aug 14, 2026 | Jason P. Rhodes | director | −2,160,516 | $25.00 |
| Aug 13, 2026 | Johanna Friedl-Naderer | officer: Chief Commercial Officer | −226 | $26.28 |
| Aug 13, 2026 | Erick Lucera | officer: Chief Financial Officer | −1,797 | $26.28 |
| Aug 13, 2026 | John Cox | director, officer: CEO & President | −4,986 | $26.28 |
Peers
- Atrium Therapeutics
TfR1 full-antibody-conjugate platform in DM1, DMD exon 44, and FSHD
- Sarepta Therapeutics
Approved PMO triplet and micro-dystrophin gene therapy hold dominant DMD market
- REGENXBIO
Pivotal DMD gene therapy (RGX-202) targeting accelerated FDA approval in 2027
- PepGen
EDO-platform DM1 oligonucleotide in Phase 2; DMD program discontinued May 2025
- Solid Biosciences
Next-gen microdystrophin gene therapy (SGT-003) in pivotal Phase 3 trial
- BioMarin
Rare-disease biotech with Pompe ERT franchise and DMD exon-51 ASO in Phase 1/2
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Dyne Therapeutics | $25.07 | −0.04% | $4.68B | — | — | — | — |
| Atrium Therapeutics | $13.64 | +0.07% | $233.3M | — | — | 9.9 | — |
| Sarepta Therapeutics | $21.05 | +0.98% | $2.20B | — | 26.3 | 1.1 | −34.3% |
| REGENXBIO | $9.65 | −0.21% | $499.4M | — | — | 2.9 | +405.7% |
| PepGen | $3.08 | −0.16% | $213.0M | — | — | — | — |
| Solid Biosciences | $9.77 | −0.10% | $961.9M | — | — | — | — |
| BioMarin | $64.67 | +0.02% | $12.50B | 165.8 | 10.4 | 3.7 | +19.9% |
| Median | 165.8 | 18.4 | 3.3 | +19.9% |